The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III trial comparing adjuvant chemotherapy with S-1 vs. surgery alone in patients with resectable biliary tract cancer (JCOG1202: ASCOT).
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Nippon Kayaku; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb Japan; Eisai; Kyowa Hakko Kirin; Lilly Japan; NanoCarrier
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxter; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
 
Kohei Nakachi
No Relationships to Disclose
 
Masaru Konishi
No Relationships to Disclose
 
Shuichi Mitsunaga
Honoraria - Ono Pharmaceutical; Toray Industries
Research Funding - ASLAN Pharmaceuticals; Bayer Yakuhin; Chugai Pharma; Merck Serono
 
Junki Mizusawa
No Relationships to Disclose
 
Katsuhiko Uesaka
Honoraria - Taiho Pharmaceutical
 
Akio Saiura
No Relationships to Disclose
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Soichiro Morinaga
No Relationships to Disclose
 
Junko Eba
No Relationships to Disclose
 
Hiroshi Katayama
No Relationships to Disclose
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Hiroshi Ishii
Honoraria - Hospira; Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Nobelpharma; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Takuji Okusaka
Honoraria - AstraZeneca Japan; Baxter; Bayer Yakuhin; Celgene; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Fujifilm; Lilly Japan; Merck Serono; Nippon Chemiphar Japan; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly Japan; Nippon Boehringer Ingelheim; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan; Baxter; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; GlaxoSmithKline K.K.; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Shizuoka Industry; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
 
Junji Furuse
Honoraria - Astellas Oncology; AstraZeneca Japan; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Novartis; Pfizer; Sawai Pharmaceutical Co; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Oncology; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Shionogi; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; J-Pharma; Janssen; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; NanoCarrier; Novartis; OncoTherapy Science; Ono Pharmaceutical; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha; Zeria Pharmaceutical